YolTech Therapeutics Raises Over RMB 300 Million in Series B Led by AstraZeneca CICC Medical Industry Fund | Unity Ventures Portfolio News
The biopharmaceutical company with the most in-vivo gene-editing drug candidates in clinical-stage pipelines globally
"
Unity Ventures portfolio company YolTech Therapeutics today announced the completion of a Series B financing round exceeding RMB 300 million.
YolTech focuses on developing in vivo gene editing therapeutics based on mRNA-LNP delivery. The company has successfully developed next-generation gene editors YolCas and base editors YolBE, and obtained proprietary novel lipid nanoparticles (LNPs) that enable more efficient in vivo delivery. Currently, all four of YolTech's product candidates have entered clinical stages, making it the biopharmaceutical company with the most in vivo gene editing drug candidates in clinical development globally.
Unity Ventures believes that compared to ex vivo gene editing approaches — where cells are edited outside the body and then transplanted back — LNP-delivered in vivo gene editing maintains safety and therapeutic efficacy while reducing patient burden, simplifying process control and scale-up, and most importantly, expanding the range of targetable organs for gene editing.
YolTech is a rare domestic team possessing both industrial-grade LNP capabilities and original base editor research capabilities. We are optimistic about the prospects of LNP-delivered in vivo gene editing and the team's exceptional execution ability, and look forward to YolTech becoming a leader in in vivo gene editing therapeutics.
"
Unity Ventures portfolio company YolTech Therapeutics today announced the completion of a Series B financing round exceeding RMB 300 million. The round was led by the AstraZeneca CICC Medical Industry Fund, with participation from Pine VC, Tianjin Venture Capital, and Xineng Venture Capital. Existing shareholders Qiyun K2VC, Farwing Capital, and Decheng Capital increased their stakes.
Founded in 2021, YolTech is dedicated to developing in vivo gene editing therapeutics with the potential for "one dose, lifelong cure."
The company has assembled a world-class R&D team in gene editing and established high-throughput gene editor mining and evolution platforms, as well as LNP delivery platforms targeting different tissues and organs. Leveraging these platforms, YolTech developed globally proprietary efficient gene editing tools YolCas and base editors YolBE, and the lipid nanoparticle delivery system Yol-LNPs.
In 2024, YolTech's independently developed YOLT-201 injection for ATTR amyloidosis became China's first LNP-delivered in vivo gene editing drug candidate to enter registrational clinical trials.
Since then, the company has continued to expand its pipeline, with four in vivo gene editing drug candidates now in clinical stages, covering major rare and common diseases including transthyretin amyloidosis (ATTR), familial hypercholesterolemia (HeFH), primary hyperoxaluria type 1 (PH1), and beta-thalassemia/sickle cell disease (β-Thalassemia/SCD).
Meanwhile, YolTech has established a GMP-compliant commercial manufacturing facility for in vivo gene editing therapeutics, providing solid support for clinical trials and subsequent commercialization.
With four products successively entering clinical stages, YolTech has become the in vivo gene editing drug development company with the most clinical-stage pipeline candidates globally.
Among these, the company's first China-US dual-filing project, YOLT-101, has received Investigational New Drug (IND) approvals from both the FDA and China's Center for Drug Evaluation (CDE). The China rights for this product have been licensed to Shenzhen Salubris Pharmaceuticals, a leading domestic cardiovascular company, whose established clinical and commercial infrastructure is expected to accelerate the product's development and launch in China.
YolTech founder and CEO Yuxuan Wu said: "We are grateful for the trust and support of our new and existing investors. YolTech will continue to be driven by original innovation and clinical value, focused on translating world-leading in vivo gene editing technology into truly therapeutic innovations that bring breakthrough changes to more patients."
AI Entrepreneurship and Investment: Truth or Dare | Unity Ventures AI Night
